Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Nanotech Indonesia Global Tbk (NANO.JK)
South Tangerang, ID
PT Nanotech Indonesia Global Tbk is a technology firm that specializes in advanced research and development (R&D) and technology services. Its core focus areas include materials engineering and the broader domain of nanotechnology. The company's activities span a variety of industries, such as materials science, healthcare, aquaculture, quality inspection, real estate, and education. Among its diverse offerings are R&D initiatives, engineering solutions, the supply of specialized nano equipment and materials, and comprehensive talent development and training programs. Established in 2005, this enterprise is headquartered in South Tangerang, Indonesia, and operates as a subsidiary of PT Nanotech Investama Sedaya.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.70% | +0.00% | -31.58% | -40.91% | -50.00% | -48.00% | -3.70% | +23.81% | -76.36% | -76.36% | -76.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%-37.2% Q4'25: -67.9% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+92.0% ★ Q4'25: +653.9% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+1.4% Q4'25: +163.8% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+4.4% Q4'25: +4.1% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+1.5% Q4'25: +1.7% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×2.62× Q4'25: 2.04× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ahmad Fathoni | Secretary | — | male |
| Alfian Noviyanto | Director of Technology & Engineering and Director | — | male |
| Intania Permata | Head of UAI | — | female |
| Kurniawan Eko Saputro | Director of Operations & Director | — | male |
| Mochamad Arief Iskandar | Director of Business & Director | — | male |
| Suryandaru | President Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NANO.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
